Overview
- RBC Capital lifted its CRISPR Therapeutics price target to $50 and kept a Sector Perform rating after third-quarter underperformance.
- RBC noted Casgevy revenue of $17 million in Q3 versus a $41 million consensus estimate, and reported infusions fell to 10 from 16 in Q2.
- Vertex projects over $100 million in total Casgevy revenue for 2025, which RBC interprets as more than $39 million in expected Q4 sales.
- Yahoo Finance data show an average price target of $82.41, implying roughly 58% upside, even as the stock fell about 23% over the past month.
- Citizens reiterated an $86 target, highlighting Phase 1 CTX310 data with significant reductions in circulating ANGPTL3 that support the in‑vivo program.